Sugi Predict

Sugi Predict / Compounds / SCHEMBL503529

SCHEMBL503529

SCHEMBL503529

O=C(O)c1ccc2c(c1)-c1ccccc1-2

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPRC P08575 2/20 0.84
▸ TTR P02766 2/20 0.73
▸ KMT2A Q03164 4/20 0.66
▸ POLB P06746 1/20 0.66
▸ SRD5A2 P31213 2/20 0.60
▸ SRD5A1 P18405 1/20 0.60
▸ CHEK1 O14757 1/20 0.58
▸ S100A4 P26447 1/20 0.57
▸ CYP2C8 P10632 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ MAPT P10636 1/20 0.53
▸ CDC25A P30304 1/20 0.53
▸ CDC25B P30305 1/20 0.53
▸ CTDSP1 Q9GZU7 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ DAO P14920 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10688924 0.98 PTPRC (0.81) PTPRCTTRKMT2APOLBSRD5A2
SCHEMBL69805 0.93 PTPRC (0.72) PTPRCTTRKMT2APOLBSRD5A2
SCHEMBL68062 0.93 PTPRC (0.72) PTPRCTTRKMT2APOLBSRD5A2
SCHEMBL4074222 0.92 PTPRC (1.00) PTPRCTTRKMT2APOLBSRD5A2
SCHEMBL3100326 0.92 PTPRC (0.92) PTPRCTTRKMT2APOLBSRD5A2
Hydrochloric Acid SCHEMBL11425710 0.90 PTPRC (0.69) PTPRCTTRKMT2APOLBSRD5A2
Hydrochloric Acid SCHEMBL6925907 0.90 PTPRC (0.69) PTPRCTTRKMT2APOLBSRD5A2
Hydrochloric Acid SCHEMBL7086253 0.90 PTPRC (0.69) PTPRCTTRKMT2APOLBSRD5A2
Hydrochloric Acid SCHEMBL5667643 0.90 PTPRC (0.69) PTPRCTTRKMT2APOLBSRD5A2
SCHEMBL292802 0.87 TTR (0.96) PTPRCTTRKMT2APOLBCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 — — US claimed
US-4507462-A CROSSLINKING AMINOKETONE ETHERS POLYMER SCIENCE (US) 1985-03-26 — — US claimed
EP-0072180-A1 Low molecular weight aromatic polymers with biphenylene end groups POLYMER SCIENCES CORPORATION (US) 1983-02-16 — — EP claimed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 — — US disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
US-8435718-B2 Upper layer-forming composition and photoresist patterning method JSR CORPORATION (JP) 2013-05-07 — — US disclosed
US-5703083-A THERAPY FOR PSYCHOLOGICAL DISORDERS NEUROGEN CORPORATION (US) 1997-12-30 — — US disclosed
WO-1997038990-A1 NOVEL N-AMINOALKYL-1-BIPHENYLENYL-2-CARBOXAMIDES; NEW DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1997-10-23 — — WO disclosed
US-4507462-A CROSSLINKING AMINOKETONE ETHERS POLYMER SCIENCE (US) 1985-03-26 — — US disclosed
EP-0072180-A1 Low molecular weight aromatic polymers with biphenylene end groups POLYMER SCIENCES CORPORATION (US) 1983-02-16 — — EP disclosed
US-4269953-A Method of crosslinking aromatic thermoplastic polymers using a biphenylene terminated compound GENERAL DYNAMICS CORPORATION (US) 1981-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 PTPRC 1409/4885TTR 2094/4885KMT2A 1624/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 PTPRC 2222/4885TTR 55/4885KMT2A 4601/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 PTPRC 1839/4885TTR 22/4885KMT2A 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.